* asymptomatic patients * patients already taking asa and other anti-coagulant / anti-platelet therapies including but not limited to clopidogrel, heparin, low molecular weight heparin, coumadin, apixaban. * pregnant patients or prisoners * history of gi bleeding or peptic ulcer disease, or spontaneous bleeding from other sites * thrombocytopenia (platelets \<130,000/ul) at time of covid diagnosis * anemia at time of covid diagnosis (defined as hemoglobin level \<12 g/dl in men or \<11 g/dl in women)22 * history of chronic kidney disease * concurrent use of nonsteroidal anti-inflammatory drugs, or steroids * hypervitaminosis d and associated risk factors: renal failure, liver failure, hyperparathyroidism, sarcoidosis, histoplasmosis * known allergy to aspirin * inability to tolerate oral medications * known history of aspirin-induced asthma * history of bleeding problems * patients who cannot avoid drinking 3 or more alcoholic drinks every day during the 30-day course of asa treatment * patients who cannot stop taking other nonprescription nsaids (ibuprofen, naproxen, or others) during the 30-day course of asa treatment * patients requiring hospitalization (for any reason) at time of screening * patients taking or who plan to take on an outpatient basis remdisivir, dexamethasone, or other therapies for treatment of covid

* asymptomatic patients * patients already taking asa and other anti-coagulant / anti-platelet therapies including but not limited to clopidogrel, heparin, low molecular weight heparin, coumadin, apixaban. * pregnant patients or prisoners * history of gi bleeding or peptic ulcer disease, or spontaneous bleeding from other sites * thrombocytopenia (platelets \<130,000/ul) at time of covid diagnosis * anemia at time of covid diagnosis (defined as hemoglobin level \<12 g/dl in men or \<11 g/dl in women)22 * history of chronic kidney disease * concurrent use of nonsteroidal anti-inflammatory drugs, or steroids * hypervitaminosis d and associated risk factors: renal failure, liver failure, hyperparathyroidism, sarcoidosis, histoplasmosis * known allergy to aspirin * inability to tolerate oral medications * known history of aspirin-induced asthma * history of bleeding problems * patients who cannot avoid drinking 3 or more alcoholic drinks every day during the 30-day course of asa treatment * patients who cannot stop taking other nonprescription nsaids (ibuprofen, naproxen, or others) during the 30-day course of asa treatment * patients requiring hospitalization (for any reason) at time of screening * patients taking or who plan to take on an outpatient basis remdisivir, dexamethasone, or other therapies for treatment of covid

- asymptomatic patients - patients already taking asa and other anti-coagulant / anti-platelet therapies including but not limited to clopidogrel, heparin, low molecular weight heparin, coumadin, apixaban. - pregnant patients or prisoners - history of gi bleeding or peptic ulcer disease, or spontaneous bleeding from other sites - thrombocytopenia (platelets <130,000/ul) at time of covid diagnosis - anemia at time of covid diagnosis (defined as hemoglobin level <12 g/dl in men or <11 g/dl in women)22 - history of chronic kidney disease - concurrent use of nonsteroidal anti-inflammatory drugs, or steroids - hypervitaminosis d and associated risk factors: renal failure, liver failure, hyperparathyroidism, sarcoidosis, histoplasmosis - known allergy to aspirin - inability to tolerate oral medications - known history of aspirin-induced asthma - history of bleeding problems - patients who cannot avoid drinking 3 or more alcoholic drinks every day during the 30-day course of asa treatment - patients who cannot stop taking other nonprescription nsaids (ibuprofen, naproxen, or others) during the 30-day course of asa treatment - patients requiring hospitalization (for any reason) at time of screening - patients taking or who plan to take on an outpatient basis remdisivir, dexamethasone, or other therapies for treatment of covid

- asymptomatic patients - patients already taking asa and other anti-coagulant / anti-platelet therapies including but not limited to clopidogrel, heparin, low molecular weight heparin, coumadin, apixaban. - pregnant patients or prisoners - history of gi bleeding or peptic ulcer disease, or spontaneous bleeding from other sites - thrombocytopenia (platelets <130,000/ul) at time of covid diagnosis - anemia at time of covid diagnosis (defined as hemoglobin level <12 g/dl in men or <11 g/dl in women)22 - history of chronic kidney disease - concurrent use of nonsteroidal anti-inflammatory drugs, or steroids - hypervitaminosis d and associated risk factors: renal failure, liver failure, hyperparathyroidism, sarcoidosis, histoplasmosis - known allergy to aspirin - inability to tolerate oral medications - known history of aspirin-induced asthma - history of bleeding problems - patients who cannot avoid drinking 3 or more alcoholic drinks every day during the 30-day course of asa treatment - patients who cannot stop taking other nonprescription nsaids (ibuprofen, naproxen, or others) during the 30-day course of asa treatment - patients requiring hospitalization (for any reason) at time of screening - patients taking or who plan to take on an outpatient basis remdisivir, dexamethasone, or other therapies for treatment of covid